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Objective: Little data on the role of neoadjuvant chemotherapy for
advanced penile carcinoma are available. We describe the experiences
at our institute.
Methods: A total of 20 patients received neoadjuvant chemotherapy for
downstaging of irresectable disease in the period from 1972 until August
2005. During this 34-yr period, five different chemotherapeutic regimens
were used. We evaluated clinical tumour response, chemotherapeutic
toxicity, rate and type of subsequent surgery, histopathologic features,
and long-term clinical outcome.
Results: An objective tumour response was achieved in 12 of 19 evaluable
patients. Overall 5-yr survival was 32%. A significant difference (p = 0.012)
in survival was found between responders (5-yr survival 56%) and non-
responders (all patients died within 9 mo). Nine responders underwent
subsequent surgery with curative intent. Eight of them were long-term
survivors without evidence of recurrent disease. Three nonresponders
were operated on to improve local control. All died within 8 mo after
surgery. Toxicity of chemotherapy was high with three toxic deaths and
discontinuation of treatment in one patient.
Conclusions: Of 20 patients with advanced penile carcinoma, 12 were
responsive to neoadjuvant chemotherapy and 8 were long-term survivors
after subsequent surgery. These results suggest that neoadjuvant
chemotherapy is a valuable treatment option for patients with irresect-
able penile carcinoma, which is otherwise considered incurable. Surgery
should be performed only in patients showing clinical response to
chemotherapy because prognosis for nonresponding patients who under-
went surgery was dismal and local control was not improved.
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While therapy for local and locoregionally metasta-
sised penile carcinoma is straightforward, a signifi-
cant number of patients present with irresectable
disease, that is, fixed inguinal lymph nodes or ino-
perable locally advanced disease. Even in advanced
cases, haematogenic spread is rare. Distant metas-
tases are present in 1–2% of patients at initial
presentation [1]. Patient delay is an important factor
explaining presentation in such advanced state of
disease.
If left untreated, prognosis of irresectable disease
is ominous, with a 3-yr mortality rate of >90% in
early series of untreated penile carcinoma [1–3].
Treatment options for this advanced stage of disease
are often limited to palliative radiation and che-
motherapy. However, in a selected group of patients
without evidence of distant metastasis, neoadjuvant
chemotherapy has successfully been used for down-
staging disease to enable surgery with curative
intent. Literature on this topic is fragmented, as
no large series are available and most neoadjuvant
chemotherapy cases are described as part of general
series of advanced penile carcinoma [4–8]. The aim of
this study was to assess the value of neoadjuvant
chemotherapy in 20 patients with irresectable penile
carcinoma treated at our institute.
2. Methods
2.1. Patient selection and indication for neoadjuvant
chemotherapy
We reviewed in our database all patients treated at our
institute for penile carcinoma up to August 2005. Only patients
with a minimum follow-up of 1 yr were included. Of the 477
patients who were treated in the period from 1972 until August
2005, 20 received neoadjuvant chemotherapy for downstaging
of irresectable penile carcinoma.Table 1 – Overview of chemotherapeutic treatment
Drug/combination/dose
Bleo (Bleo 15 mg iv days 1 and 3, repeated weekly until total maximum d
Bleo/Vin/MTX (Bleo 15 mg iv days 1 and 2, Vin 1 mg iv day 1, MTX 30–50
with a 1-wk interval until maximum of 12 cycles)
5-FU/Cis (5-FU 1000 mg/m2 iv days 1–5, Cis 100 mg/m2 iv day 1, repeated
until maximum of 5 cycles)
Bleo/Cis/MTX (Bleo 15 mg iv days 2–5, Cis 20 mg/m2 iv days 2–5, MTX 20
repeated with a 3-wk interval until maximum of 4 cycles)
Cis/CPT-11 (irinotecan)y (Cis 80 mg/m2 iv day 1, CPT-11 60 mg/m2 iv days
repeated with a 2-wk interval until maximum of 8 cycles)
Bleo = bleomycin; Vin = vincristine; MTX = methotrexate; 5FU = 5-fluorou
* One patient was not evaluable.
y Included in the European Organisation for Research and Treatment ofThe indication for neoadjuvant chemotherapy was down-
staging of inoperable regionally or locally advanced disease,
that is, fixed inguinal lymph nodes or irresectable locally
advanced disease in patients with sufficient performance
status and without evidence of distant metastasis (M0).
2.2. Staging
Tumour stage was (re)classified according to the 2002 TNM
classification [9] and recorded at the start of chemotherapeutic
treatment, on the basis of physical examination, radiologic
imaging, and histopathologic examination when available.
2.3. Chemotherapy
During 34 yr, five different regimens were used consecutively
(Table 1). Until 1985 single-agent therapy with bleomycin
(Bleo) was used; from 1986 until 1999 combination chemother-
apy with Bleo, vincristin (Vin), and methotrexate (MTX) was
used; and from 1999 until 2001 combination therapy of
5-fluorouracil (5FU) and cisplatin (Cis) was used. Since 2001,
a regimen containing Cis, Bleo, and MTX was used. One patient
was included in the European Organisation for Research and
Treatment of Cancer (EORTC) 30992 study protocol [10] and
treated with Cis and CPT-11 (irinotecan). Chemotherapy was
discontinued in case of tumour progression or severe toxicity.
When necessary, dose adjustments were made on the basis of
haematologic and renal toxicity.
2.4. Response
Tumour response was recorded on the basis of physical
examination and radiologic imaging at least every two cycles
and was divided into the following categories: complete
response, partial response, and stable/progressive disease.
Complete response was defined as total disappearance of
measured lesions on physical examination and imaging;
partial response as decrease of the sum of diameters of
lesions, without simultaneous increase in size of any of the
lesions or the appearance of new lesions; and stable/
progressive disease as no measurable response or increase
in summed diameter of measured lesions, as well as the




ose of 200–300 mg) 3 1 (33)
mg iv day 3, repeated 5 3 (60)
with a 3-wk interval 1 1 (100)
0 mg/m2 iv day 1, 10 6 (67)*
1, 8, and 15, 1 1 (100)
racil; Cis = cisplatin.
Cancer (EORTC) 30992 study [10].
Table 2 – Patient characteristics
Total no. of patients 20














* Neoadjuvant chemotherapy for rapidly progressing recurrence of
spindle cell carcinoma.
Fig. 1 – Overall survival probability according to clinical
response.
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Information on toxicity was obtained from patient charts and,
whenever possible, classified according to the common
terminology criteria of adverse effects [11]. In Bleo-containing
regimens, chest X-rays and on-indication lung function tests
were done to assess possible pulmonary toxicity. Regular
blood tests, including renal function, and white blood cell and
platelet counts, were done to monitor toxicity.
2.6. Surgery
The procedures performed in patients considered eligible for
subsequent surgery after chemotherapy were inguinal lymph
node dissection, pelvic lymph node dissection, and partial and
total penectomy. Some of the procedures necessitated
extended removal of surrounding soft tissue, with or without
parts of the pelvic bony structures. Reconstruction was done
with the aid of vascularised flaps.
2.7. Statistical analysis
Overall survival was defined as the date of start of neoadjuvant
chemotherapy to the last date of follow-up or death. Survival
probabilities were estimated with the Kaplan-Meier method.
For further analysis all patients receiving neoadjuvant che-
motherapy were divided into two groups: nonresponders
(stable/progressive disease) and responders (partial and com-
plete response). To analyse possible correlation with survival,
univariate analysis with a log-rank test was performed for
the following variables: response to chemotherapy, T category,
N category, tumour differentiation, and age at start of
chemotherapy. One unevaluable patient was excluded from
further analyses. All analyses were performed with the soft-
ware packages Statistical Package for the Social Scientists,
version 12.0 (SPSS Inc, Chicago, IL, USA) and SAS (SAS Institute




All 20 patients had a histopathologically proven
squamous cell carcinoma of the penis, of which one
was a spindle cell (sarcomatoid) carcinoma. (See
Table 2 for further details.)
3.2. Chemotherapy and tumour response
One patient (receiving Bleo/Cis/MTX) died of toxicity
within 2 wk after starting chemotherapy, before
tumour response could be evaluated. An objective
tumour response was measured in 12 of the
remaining 19 patients (63%), consisting of 2 com-
plete and 10 partial responses. Stable/progressive
disease was found in 7 (37%) patients. (See Table 1
for more details.)3.3. Survival
Median follow-up was 23 mo (range: 1–134). The
overall 5-yr survival was 32% (95% confidence
interval [95%CI], 17–62%). A significant difference
in survival (log-rank test; p = 0.012) was found
between patients responsive to chemotherapy and
nonresponsive patients (Fig. 1). In the group of
responders, 5-yr survival was 56% (95%CI, 34–94%),
while all nonresponders died within 9 mo after start
of treatment. No significant correlation was found
between T category ( p = 0.75), N category ( p = 0.85),
tumour differentiation ( p = 0.65), age ( p = 0.26), and
survival.
3.4. Toxicity
Severe toxicity occurred in 4 of 20 patients: 3 toxic
deaths were recorded and treatment had to be
discontinued in 1 patient. The first patient died of
e u r o p e a n u r o l o g y 5 2 ( 2 0 0 7 ) 4 8 8 – 4 9 4 491an autopsy-confirmed bleomycin pneumonia with
lung emboli, 3 mo after start of chemotherapy
(Bleo/Vin/MTX). The second patient died of trom-
boembolic complications involving brain stem
infarction, within 2 wk after the start of chemother-
apy (Bleo/Cis/MTX). The third patient died of a
bacterial pneumonia during a period of prolonged
leucopenia, 3 mo after the start of chemotherapy
(Bleo/Cis/MTX). The discontinuation of treatment
in 1 patient (Bleo/Cis/MTX) was related to severe
pulmonary toxicity (grade 3), probably caused by
bleomycin. It should be noted that 3 of the 4 patients
with severe toxicity received the Bleo/Cis/MTX regi-
men. Grade 1 and 2 nausea and increased fatigue
were almost universally reported side-effects, as was
grade 1 or 2 alopecia in a large number of patients.
3.5. Surgery
Of 20 patients treated with neoadjuvant chemother-
apy, 9 responders to chemotherapy (2 complete and
7 partial) underwent subsequent surgery. Another 3
responders were scheduled for surgery, but 2 of
them died of chemotherapeutic toxicity before they
could be operated on and 1 patient was declaredFig. 2 – Schematic overviewunfit for operation. Three nonresponders were
operated on in an attempt to improve local control.
(See Fig. 2 for more details.)
An overview of performed operations can be
found in Table 3. When needed, large skin defects
were covered with the use of vascularised flaps and
the aid of a plastic surgeon.
There was a significant difference ( p < 0.001) in
survival between the responders and nonrespon-
ders after surgery. All three nonresponders had fatal
locally recurrent disease: one patient died of bleed-
ing due to invasion in the femoral artery, and two
patients with widespread cutaneous metastases
died of infectious complications, all within 8 mo
after surgery. Only one of nine patients in the group
of responders had locally recurrent disease and died
of bleeding due to ingrowth in the femoral artery
and vein. This patient had extensive invasion in the
surrounding tissue, including the pubic and sym-
physis bones.
3.6. Histopathologic findings
No residual tumour (pT0N0) was found in the two
patients with a clinically complete response. Allof various treatments.
Table 3 – Overview of performed operations
Type of surgery* Responders (n = 9) Nonresponders (n = 3)
Inguinal lymph node dissection
Bilateral 5 0
Unilateral 1 1
Bilateral with en bloc resection of prepubic fat 3 2
Bilateral pelvic lymph node dissection 2 3
Partial penile amputation 3 1
Total penile amputation 2 1
Partial resection of pubic and symphysis bone 1 0
* More than one type of surgery per patient is possible.
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viable tumour, except for one patient with extensive
tumour spread with invasion in the pubic and
symphysis bone and prostate (pT4). The three
nonresponding patients who underwent surgery
to improve local control all had positive inguinal and
pelvic nodes (pN3), and local recurrences (as men-
tioned above) occurred within 3 mo after surgery.
Histopathologic findings were related to outcome;
pelvic lymph node involvement as well as extensive
invasion in surrounding tissue were related to short
survival.4. Discussion
The role of chemotherapy in penile carcinoma is not
well-defined. Several chemotherapeutic agents
have been reported to have an effect on this type
of tumour, both as single agents and as combination
chemotherapy, but numbers of patients in reported
series remain relatively low because of the low
incidence of this disease [4–6,8,12–17]. Neoadjuvant
chemotherapy seems to be a valid treatment option
for downstaging irresectable penile carcinoma. In
their review on advanced penile carcinoma Culkin
and Beer [1] combined results of available literature
on cisplatin-based neoadjuvant chemotherapy. A
clinical response was found in 24 of 35 patients
(69%), and 15 (43%) underwent additional surgery.
Eight (23%) remained alive without evidence of dis-
ease for 1–10 yr [1]. These results are similar to ours.
Mitropoulos et al [5] described a series of 13
patients treated with neoadjuvant cisplatin and
interferon-a2B. Response rate was 75% in 12 evalu-
able patients, and 8 (67%) remained disease-free for
21+ mo. Two patients died of metastatic disease and
the remaining two patients had a local recurrence,
for which they were successfully treated [5]. The
majority of the study population, however, were
clinically node-negative T2 and T3 tumours, so the
results are difficult to compare.Subsequent surgery after chemotherapy has an
important role in obtaining local control in advanced
disease. All but two patients undergoing surgery
still had viable residual tumour after chemother-
apeutic treatment during histopathologic examina-
tion, stressing the need for subsequent surgery.
Looking at our results, the marked difference in
survival in the group who underwent subsequent
surgery between the responder and nonresponder
groups suggests that it is wise to refrain from further
surgical treatment in the latter group because
survival rates were dismal. Moreover surgery in
these cases did not add positively to local control
in terms of wound management or pain control.
Palliation remains difficult in this category of pa-
tients, who are unresponsive to chemotherapy and
often have coexisting lymph edema, painful ulcers,
and foul smelling wounds.
Toxicity was high in our series, with three deaths
directly related to toxicity and discontinuation of
treatment because of toxicity in one patient. Toxicity
was particularly severe in the group of patients who
received Bleo/Cis/MTX. Similar results were found
in a phase 2 study on the Cis/Bleo/MTX regimen
for penile carcinoma, performed by the Southwest
Oncology Group [12]. Of the 41 evaluable patients, 5
died of toxicity and another 6 patients had one or
more life-threatening toxic episodes.
Because of the low numbers of patients, it is
difficult to accurately compare the response and
toxicity rates of the different chemotherapeutic
regimens. No specific regimen can therefore be
recommended; however, in light of the relatively
high toxicity in the Bleo/Cis/MTX group, whether the
high response rate outweighs the high rate of toxicity
in this regimen must be carefully considered.
Future challenges are ahead in optimising treat-
ment of advanced penile carcinoma. With regards
to more prevalent squamous cell carcinomas in
other areas, such as head and neck and cervix,
concomitant chemoradiation therapy has taken a
prominent role in the treatment of various stages
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significant advantage of chemoradiation therapy
over single-modality therapy in disease-free and
overall survival, although acute toxicity is poten-
tially higher [18,19]. So far, very little research has
been done in this area concerning penile carcinoma.
Another interesting option is the use of newer
tumour-active drugs, both as single agents and as
part of combination therapy. In the treatment of
squamous cell carcinomas of head and neck
(SCCHNs), a number of agents have shown promis-
ing results, while having more favourable toxicity
profiles. New active drugs include taxanes such
as paclitaxel and docetaxel, of which docetaxel has
also successfully been used as a radio sensitiser
[20,21]. A second group of agents target the epidermal
growth factor receptor, a receptor that is over-
expressed in the majority of squamous cell carcino-
mas. Examples are cetuximab (a monoclonal
antibody) and small molecule tyrosine kinase inhi-
bitors such as erlotinib and gefitinib, which all
have been shown to be active in squamous cell
carcinomas [22–25]. Concomitant cetuximab and
radiation therapy has also been shown to be superior
to radiation therapy alone in terms of survival and
locoregional control in advanced SCCHN [26].
To obtain sufficient numbers of patients required
for investigating these new therapeutic approaches,
multi-institutional studies are needed.5. Conclusions
Neoadjuvant chemotherapy appears to be a valid
treatment option for downstaging of irresectable
penile carcinoma. An objective tumour response
was found in 12 of 19 evaluable patients. Nine
patients underwent subsequent surgery with cura-
tive intent, 8 of whom were long-term survivors.
Toxicity was high in our series with a total of three
deaths due to chemotherapeutic toxicity and dis-
continuation of treatment in one patient. Subse-
quent surgery seems warranted in only patients
responsive to chemotherapy because prognosis of
operated nonresponders was dismal and local
control was not improved. Because of the different
regimens used and the relatively low number of
patients, no specific chemotherapeutic regimen can
be recommended, although the high toxicity in the
Bleo/Cis/MTX regimen should be taken into account
when considering this type of chemotherapy.
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Chemotherapy in Advanced Penile Carcinoma
Giorgio Pizzocaro
Università degli Studi di Milano-Ospedale S. Giuseppe,
Clinica Urologica, via S. Vittore 12, 20100 Milan, Italy
pizzocaro@iol.it
Squamous cell carcinoma (SCC) of the penis is an
uncommon disease in Western countries. Organ-
sparing surgery may be successful in early-stage
disease, but survival depends on nodal metastases
[1]. The occurrence of one single intranodal
metastasis does not compromise prognosis, but
multiple metastases do, and fixed inguinal or
pelvic node involvement is extremely ominous.
In these cases chemotherapy may be helpful,
without the severe side effects of desperation sur-
gery or aggressive radiotherapy [1,2].
Leijte et al [3] report results in 20 patients (of 477
patients!) who received neoadjuvant chemother-
apy for down-staging of unresectable penile
cancer from 1972 to 2005. Of course, different
regimens were used over this long time period.
Interestingly, objective responses were observed
in all regimens. Overall, 12 patients were respon-
sive and one died of acute toxicity. All 7 non-
responders died between 4 and 8 mo, despite 3
having undergone desperation surgery.
Of the 12 responders, 2 died of toxicity and one
was unfit for surgery. Eight of the 9 responders
who underwent postchemotherapy surgery are
long-term survivors. Only one patient died of
recurrence. Toxic death occurred in 3 of 10 patients
treated with the Southwestern Oncology Group
(SWOG) regimen (cis-diamminedichloroplatinum,
cisplatin [CDDP], methotrexate [MTX], bleomycin
[BLM]). This regimen has been recognised as very
active but also as very toxic and the majority of[23] Bourhis J. New approaches to enhance chemotherapy in
SCCHN. Ann Oncol 2005;16(Suppl 6):vi20–4.
[24] Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of
ZD1839 in recurrent or metastatic squamous cell carci-
noma of the head and neck. J Clin Oncol 2003;21:
1980–7.
[25] Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase
II study of erlotinib, an oral epidermal growth factor
receptor tyrosine kinase inhibitor, in patients with recur-
rent or metastatic squamous cell cancer of the head and
neck. J Clin Oncol 2004;22:77–85.
[26] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus
cetuximab for squamous-cell carcinoma of the head and
neck. N Engl J Med 2006;354:567–78.authors are using the CDDP–5-fluoruracil (PF)
combination, which is the same combination that
has been used for a long time in SCC of the head
and neck with moderately positive results [2].
Recently, taxanes (docetaxel and paclitaxel) have
been introduced in the PF combination for locally
advanced head and neck SCC. A recent large phase
3 randomised study [4] reported 14% complete
response rate in 193 patients treated with PF versus
33% in 189 treated with Taxol–PF (TPF), with good
tolerability. Assuming that penile SCC has a similar
responsivity to chemotherapy as SCC of the head
and neck, patients with fixed or recurrent inguinal
metastases or large pelvic involvement could be
treated with TPF in prospective cooperative stu-
dies. Preliminary personal results are encouraging.
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